Radiation Oncology
Expert insights on radiation treatment planning, techniques, toxicity management, and multimodal cancer care.
Recent Discussions
How would you approach treatment failures with squamous cell carcinoma-keratoacanthoma-type lesions that did not respond to a standard SRT regimen after many sessions?
Most keratoacanthoma-type cutaneous squamous cell carcinomas that I see are bulky, and superficial radiotherapy (SRT) would not provide an adequate depth of radiation penetration to eliminate the carcinoma cells. If radiotherapy is being used for a bulky tumor like this, a higher energy form of more...
In patients with early-stage follicular lymphoma undergoing definitive RT, do you approach grade 3a disease any differently than grade 1-2 (radiation dose, fields/margins, systemic therapy)?
Our philosophy is based on whether it is grade 3A or 3B. If it is 3A, then we treat like low grade lymphoma with RT (similar dose and principle) but if it is 3B, then treat with chemotherapy +/_ RT like diffuse large B cell lymphoma.
Is there evidence to support or argue against intermittent fasting for cancer patients?
This is a complex topic with many permutations of dietary interventions similar to fasting such as calorie restriction and “fasting mimicking”, but as it pertains to pure fasting, I know of a few small studies which characterize fasting around the time of chemotherapy infusions (Raffaghello et al., ...
Would you boost a resected axilla if extra-nodal extension is found in a patient with breast cancer?
The data on ECE for breast suggests it increases the risk of recurrence in undissected axilla or supraclav region. We don’t boost ECE region and most of the time don’t even include the dissected axilla with ECE in treatment volume unless the dissection is inadequate.
How would you treat a primary angiosarcoma arising in the skull, excised with initial excisional biopsy?
I would try to get some more information first. Is this a cutaneous primary invading into skull, or a lesion arising primarily in the skull? Is there any evidence of violation (tumor or iatrogenic) through calvarium such that dura is threatened? I would stage with a careful skin exam for any cutaneo...
Given the criticism of GOG 88 and in light of various other recent data, would you deliver definitive XRT in place of inguinal lymph node dissection?
Despite GOG 88 findings, a number of retrospective studies have suggested that regional prophylactic RT is an effective method of preventing groin recurrences with minimal morbidity when appropriately delivered. (Combined across retrospective series, the incidence of groin recurrence following treat...
How does metaplastic thymoma histology impact your decision regarding adjuvant radiation?
This is a good question. I honestly have never seen this histology, and I help write the UpToDate thymoma section and am a thymoma enthusiast (meaning I like to read about it/treat it, not to have it). Thymomas really run the spectrum of aggressiveness, and the approach to them in the adjuvant setti...
How do you differentiate demoralization from depression during cancer treatment?
Certainly a key question in all referrals for "depression" in psycho-oncology. The two syndromes have areas of overlap and are not mutually exclusive. Clinical depression in cancer looks much like it would in any other context, though non-specific physical symptoms that can be caused by the cancer/t...
Would you offer SBRT for intraprostatic recurrence after definitive RT in a patient with contraindications to ablation and brachytherapy?
This is a very nice review on this topic, highlighting brachytherapy and SBRT for salvage after previous EBRT - A Systematic Review and Meta-analysis of Local Salvage Therapies After Radiotherapy for Prostate Cancer (MASTER) - ScienceDirect.
Would you give immunotherapy after neoadjuvant gem-cis for bladder cancer if cystectomy is being postponed for months due to non-autoimmune/unrelated comorbidities?
Delay in cystectomy regardless of the use of neoadjuvant chemotherapy is associated with compromised survival outcomes (Chu et al., PMID 30840335) and if a patient receives neoadjuvant chemotherapy and is unable to undergo cystectomy for months due to comorbidities, there is no clear data to support...